Skip to main content
Clinical Trials/ISRCTN65652441
ISRCTN65652441
Completed
Phase 3

A randomised controlled trial of prolonged treatment with darbepoetin alpha (EPO), with or without recombinant human granulocyte colony stimulating factor (G-CSF), versus best supportive care in patients with low-risk myelodysplastic syndromes (MDS)

Barts and The London NHS Trust (UK)0 sites1,200 target enrollmentJune 24, 2010

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Topic: National Cancer Research Network
Sponsor
Barts and The London NHS Trust (UK)
Enrollment
1200
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 24, 2010
End Date
December 11, 2009
Last Updated
7 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Barts and The London NHS Trust (UK)

Eligibility Criteria

Inclusion Criteria

  • 1\. A confirmed diagnosis of MDS \- WHO type:
  • 1\.1\. Refractory anaemia (RA)
  • 1\.2\. Hypoplastic RA ineligible for or failed immunosuppressive therapy (ALG, cyclosporine)
  • 1\.3\. Refractory anaemia with ring sideroblasts (RARS)
  • 1\.4\. Refractory cytopenia with multilineage dysplasia
  • 1\.5\. Myelodysplastic syndrome unclassifiable
  • 2\. IPSS low or Int\-1, but with BM blasts less than 5%
  • 3\. A haemoglobin concentration of less than 10 g/dl and/or red cell transfusion dependence
  • 4\. Written informed consent
  • 5\. Aged more than 18 years old, no upper limit, either sex

Exclusion Criteria

  • 1\. MDS with bone marrow blasts greater than or equal to 5%
  • 2\. Myelodysplastic syndrome associated with del(5q)(q31\-33\) syndrome
  • 3\. Chronic myelomonocytic leukaemia (monocytes greater than 1\.0 x 10^9/l)
  • 4\. Therapy\-related MDS
  • 5\. Splenomegaly, with spleen greater than or equal to 5 cm from left costal margin
  • 6\. Platelets less than 30 x 10^9/l
  • 7\. Uncorrected haematinic deficiency
  • 8\. Age less than 18 years
  • 9\. Woman who are pregnant or lactating
  • 10\. Women of child bearing age unless using reliable contraception

Outcomes

Primary Outcomes

Not specified

Similar Trials